Compare FIGS & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIGS | ZLAB |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | 2021 | 2017 |
| Metric | FIGS | ZLAB |
|---|---|---|
| Price | $12.41 | $18.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $15.93 | ★ $49.60 |
| AVG Volume (30 Days) | ★ 4.0M | 631.0K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 850.00 | 38.46 |
| EPS | ★ 0.03 | N/A |
| Revenue | $419,591,000.00 | ★ $460,156,000.00 |
| Revenue This Year | $14.09 | $9.75 |
| Revenue Next Year | $7.72 | $26.03 |
| P/E Ratio | $414.83 | ★ N/A |
| Revenue Growth | ★ 59.47 | 15.33 |
| 52 Week Low | $4.25 | $15.96 |
| 52 Week High | $17.48 | $44.34 |
| Indicator | FIGS | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.96 | 40.09 |
| Support Level | $10.76 | $18.29 |
| Resistance Level | $15.83 | $19.64 |
| Average True Range (ATR) | 0.71 | 1.02 |
| MACD | -0.06 | -0.22 |
| Stochastic Oscillator | 33.61 | 14.60 |
FIGS Inc is a healthcare apparel company. It designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear, and other healthcare apparel. The company sells products mainly through its direct-to-consumer (DTC) digital platform, consisting of its website, mobile app, and B2B business (TEAMS). It also operates physical retail stores, which are called Community Hubs, providing a retail experience for healthcare professionals. The company generates maximum revenue from the sale of scrubwear products. Geographically, it derives maximum revenue from the United States, followed by the rest of the world.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.